ATP1A2 as a subtype-associated candidate prognostic biomarker in breast cancer: an integrated transcriptomic, epigenetic and in vitro analysis
Epigenomics · 03.10.2026 · 18 (10) · 1233-1247
DOI: 10.1080/17501911.2026.2744072 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epigenomics, online erschienen am 08.10.2026. Verfasst von Daniel Rodrigues de Bastos und 5 weiteren Autor:innen. Beteiligte Einrichtung: Facultad de Ciencias Médicas, Universidad Privada del Este, Ciudad del Este, Paraguay. Hauptthemen laut MEDLINE: Breast Neoplasms, Biomarkers, Tumor, Epigenesis, Genetic. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: To evaluate ATP1A2 as a subtype-associated candidate prognostic biomarker in breast cancer by integrating transcriptomic, epigenetic, immune, survival, and in vitro expression analyses. RESEARCH DESIGN AND METHODS: ATP1A2 mRNA expression was analyzed using TCGA-BRCA data from 1,087 patients and compared across clinicopathological and molecular features. DNA methylation was evaluated across twelve ATP1A2 CpG sites, and RT-qPCR was performed in breast cancer cell lines representing luminal, HER2-enriched, and triple-negative models under basal conditions and after therapeutic exposure. RESULTS: ATP1A2 expression was reduced in breast tumors compared with tumor-adjacent normal breast tissue and followed a subtype-dependent pattern, with the lowest levels in basal-like tumors and the highest in luminal A and normal-like tumors. Low ATP1A2 expression was associated with aggressive clinicopathological features, hormone receptor negativity, HER2 positivity, and non-luminal subtypes. High ATP1A2 expression predicted improved overall and disease-free survival and remained independently associated with overall survival. Basal-like tumors displayed ATP1A2 amplification despite reduced mRNA expression, suggesting possible passenger-gene behavior within the 1q21-q23 amplicon. Methylation and immune analyses suggested epigenetic and microenvironmental influences, whereas in vitro assays showed treatment-associated transcriptional modulation. CONCLUSIONS: ATP1A2 s associated with breast cancer subtype and independently predicts overall survival, warranting further independent validation. Breast cancer is not a single disease. Different tumor types can behave differently and respond differently to treatment. In this study, we investigated ATP1A2, a gene involved in maintaining the balance of sodium and potassium in cells, to determine whether its activity is linked to breast cancer behavior and patient outcomes. We analyzed public data from 1,087 patients and also measured ATP1A2 activity in several breast cancer cell lines before and after treatment with radiation or chemotherapy. ATP1A2 activity was generally lower in more aggressive breast cancer types, especially basal-like and HER2-enriched tumors. Higher ATP1A2 activity was associated with better survival. We also found that chemical changes to DNA that can affect gene activity, as well as the mix of immune and other cells within tumors, may be related to ATP1A2 levels. In laboratory experiments, ATP1A2 activity changed after radiation and chemotherapy, although the response differed between cell lines and treatments. These findings suggest that ATP1A2 may be a useful marker of breast cancer biology and prognosis. However, further studies in independent patient groups and laboratory models are needed before ATP1A2 can be considered for clinical use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Facultad de Ciencias Médicas, Universidad Privada del Este, Ciudad del Este, Paraguay.
- Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
- Departamento de Farmácia Oncológica, Associação Paulista para o Desenvolvimento da Medicina (SPDM), São Paulo, Brazil.
- Center for Translational Research in Oncology, Instituto do Cancer do Estado de São Paulo ICESP, Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo FMUSP HC, São Paulo, Brazil.
- Comprehensive Center for Precision Oncology, Universidade de São Paulo, São Paulo, Brazil.
- Department of Radiology and Oncology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
ORCID-Profile: Daniel Rodrigues de Bastos, Renan Gomes do Nascimento, Maiza Vitoria Aguiar Silva Oliveira, Sandra Gonzalez L, Marilaura Chamorro, Ricardo Cesar Cintra
Zitieren
APA
de Bastos, D. R., do Nascimento, R. G., Oliveira, M. V. A. S., Gonzalez L, S., Chamorro, M., & Cintra, R. C. (2026). ATP1A2 as a subtype-associated candidate prognostic biomarker in breast cancer: an integrated transcriptomic, epigenetic and in vitro analysis. Epigenomics, 18(10), 1233-1247. https://doi.org/10.1080/17501911.2026.2744072
Vancouver
de Bastos DR, do Nascimento RG, Oliveira MVAS, Gonzalez L S, Chamorro M, Cintra RC. ATP1A2 as a subtype-associated candidate prognostic biomarker in breast cancer: an integrated transcriptomic, epigenetic and in vitro analysis. Epigenomics. 2026;18(10):1233-1247. doi:10.1080/17501911.2026.2744072
BibTeX
@article{deBastos2026,
author = {de Bastos, Daniel Rodrigues and do Nascimento, Renan Gomes and Oliveira, Maiza Vitoria Aguiar Silva and Gonzalez L, Sandra and Chamorro, Marilaura and Cintra, Ricardo Cesar},
title = {ATP1A2 as a subtype-associated candidate prognostic biomarker in breast cancer: an integrated transcriptomic, epigenetic and in vitro analysis},
journal = {Epigenomics},
year = {2026},
volume = {18},
number = {10},
pages = {1233--1247},
doi = {10.1080/17501911.2026.2744072}
}
EUVIMED